Woodline Partners LP Biocryst Pharmaceuticals Inc Transaction History

Woodline Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $10.9 Million - $16.2 Million	-1,369,403 Reduced 66.12%	701,580 $5.85 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $21.7 Million - $29.4 Million	2,070,983 New	2,070,983 $23.8 Million
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $1.15 Million - $2.12 Million	-155,844 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $2.4 Million - $6.14 Million	-712,864 Reduced 82.06%	155,844 $1.16 Million
Q3 2020 Nov 16, 2020	SELL	$3.43 - $5.53 $2.48 Million - $3.99 Million	-722,133 Reduced 45.39%	868,708 $2.98 Million
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $638,996 - $1.89 Million	336,314 Added 26.81%	1,590,841 $7.58 Million
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $1.86 Million - $4.78 Million	-1,163,302 Reduced 48.11%	1,254,527 $2.51 Million
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $3.84 Million - $8.34 Million	2,417,829 New	2,417,829 $8.34 Million

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.